Teva Announces Proposal To Acquire Mylan In Cash And Stock Deal - Quick Facts

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced a proposal to acquire all of the outstanding shares of Mylan N.V. (MYL) in a transaction valued at $82.00 per Mylan share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock. Teva stated that its proposal provides Mylan stockholders with a more attractive alternative to Mylan's proposed acquisition of Perrigo Company plc (PRGO), as well as to Mylan on a standalone basis.

Teva believes the combination would be significantly accretive to non-GAAP EPS, including expected non-GAAP EPS accretion in the mid-teens in the first year, and approaching 30% by the third year. The company expects that the proposed transaction can be completed by year-end 2015.